Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study.

ABSTRACT:

Background

While adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) have improved invasive disease-free survival (iDFS) in ER-positive, HER2-negative early breast cancer (EBC) in the MonarchE and NATALEE trials, their real-world applicability in Denmark remains unclear. This study evaluates Danish patients meeting comparable high-risk criteria and their outcomes, hypothesizing that a substantial proportion could benefit from additional adjuvant treatment options.

Methods

Patients with ER-positive, HER2-negative EBC, diagnosed 2014-2019, who met MonarchE and/or NATALEE eligibility, were included and categorized as intermediate or high risk corresponding to trial definitions. Outcomes were overall survival (OS), iDFS, cumulative incidence of distant recurrence-free surviv

SUBMITTER: Jacobsen IC 

PROVIDER: S-EPMC12625151 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature